Xeris Biopharma Shares Rise on Expectation of Significant Full-Year Revenue Growth

Dow Jones

06 Mar

Xeris Pharmaceuticals Inc-1.10%Post-market

By Sabela Ojea

Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025.

The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021. Shares have plunged 81% over the past 12 months.

The biopharmaceutical company projected full-year revenue of $255 million to $275 million, representing growth of over 30% at the mid-point range.

The Chicago company also expects adjusted earnings before interest, taxes, depreciation and amortization to remain positive going forward, Finance Chief Steven Pieper said.

"Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris," Pieper said.

The company's outlook came as it reported a significant increase in product revenue in the fourth quarter.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

March 06, 2025 12:10 ET (17:10 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517519323"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517519323\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2517519323?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-07 01:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517519323","market":"sg","top_or_hot":-1,"title":"Xeris Biopharma Shares Rise on Expectation of Significant Full-Year Revenue Growth","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025. \n</p>\n<p>\n  The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021. Shares have plunged 81% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company projected full-year revenue of $255 million to $275 million, representing growth of over 30% at the mid-point range. \n</p>\n<p>\n  The Chicago company also expects adjusted earnings before interest, taxes, depreciation and amortization to remain positive going forward, Finance Chief Steven Pieper said. \n</p>\n<p>\n  \"Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris,\" Pieper said. \n</p>\n<p>\n  The company's outlook came as it reported a significant increase in product revenue in the fourth quarter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 06, 2025 12:10 ET (17:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xeris Biopharma Shares Rise on Expectation of Significant Full-Year Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXeris Biopharma Shares Rise on Expectation of Significant Full-Year Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-07 01:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025. \n</p>\n<p>\n  The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021. Shares have plunged 81% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company projected full-year revenue of $255 million to $275 million, representing growth of over 30% at the mid-point range. \n</p>\n<p>\n  The Chicago company also expects adjusted earnings before interest, taxes, depreciation and amortization to remain positive going forward, Finance Chief Steven Pieper said. \n</p>\n<p>\n  \"Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris,\" Pieper said. \n</p>\n<p>\n  The company's outlook came as it reported a significant increase in product revenue in the fourth quarter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 06, 2025 12:10 ET (17:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XERS","symbol_name":"Xeris制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2517519323","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517519323","pubTimestamp":1741281000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025.The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021. Shares have plunged 81% over the past 12 months.The biopharmaceutical company projected full-year revenue of $255 million to $275 million, representing growth of over 30% at the mid-point range.The Chicago company also expects adjusted earnings before interest, taxes, depreciation and amortization to remain positive going forward, Finance Chief Steven Pieper said.\"Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris,\" Pieper said.The company's outlook came as it reported a significant increase in product revenue in the fourth quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"XERS":"Xeris制药"},"translate_title":"Xeris Biopharma股价因全年收入大幅增长的预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025. \n\n\n  The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021. Shares have plunged 81% over the past 12 months. \n\n\n  The biopharmaceutical company projected full-year revenue of $255 million to $275 million, representing growth of over 30% at the mid-point range. \n\n\n  The Chicago company also expects adjusted earnings before interest, taxes, depreciation and amortization to remain positive going forward, Finance Chief Steven Pieper said. \n\n\n  \"Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris,\" Pieper said. \n\n\n  The company's outlook came as it reported a significant increase in product revenue in the fourth quarter. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2025 12:10 ET (17:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."

Consult now
Download APP
Scan QR code to download the app.